Cardiac involvement in Dengue Haemorrhagic Fever.

We studied 17 consecutive patients of Dengue Haemorrhagic Fever/Dengue Shock Syndrome (DHF/DSS) to assess cardiac function by radionuclide ventriculography, echocardiography and electrocardiography (ECG) during the epidemic of Dengue virus type-2 (DEN-2) in Delhi, India (1996). Case definitions laid down by the WHO were followed. Fourteen patients were seropositive for Dengue infection. In radionuclide ventriculography study, the mean left-ventricular ejection fraction was 41.69 (5.04% (range 33-49%) and 7 patients had an ejection fraction less than 40%, global hypokinesia was detected in 12 (70.59%) patients. In echocardiography, the mean ejection fraction was 47.06 (3.8%). Eight patients had Dengue Shock Syndrome and the mean ejection fraction was 39.63% (4.97% in radionuclide ventriculography, out of which 5 patients had an ejection fraction below 40%. To find out the nature of myocardial involvement, 99m Tc-pyrophosphate imaging was done in 4 patients and it was discontinued further because no myocardial necrosis was detected in those patients. Five patients had ST and T changes in the electrocardiogram, radionuclide ventriculography and echocardiography revealed no abnormalities after 3 weeks of follow up and the ejection fraction was more than 50% in all cases. Global hypokinesia also improved and ECG changes reverted back to normal within 3 weeks. Acute reversible cardiac insult may be noticed in Dengue Haemorrhagic Fever/Dengue Shock Syndrome and could be responsible for hypotension/shock seen in some of these patients. Further studies are required to establish the pathogenic mechanisms of cardiac dysfunction in patients with Dengue Haemorrhagic Fever/Dengue Shock Syndrome.

[1]  S. Kabra,et al.  Dengue haemorrhagic fever in children in Delhi. , 1992, Bulletin of the World Health Organization.

[2]  H. Schultheiss,et al.  Treatment of chronic myocarditis with corticosteroids. , 1995, European heart journal.

[3]  A. Matsumori,et al.  Immunomodulating agents for the management of heart failure with myocarditis and cardiomyopathy--lessons from animal experiments. , 1995, European heart journal.

[4]  Rehle Tm Classification, distribution and importance of arboviruses. , 1989 .

[5]  A. Sabin Research on dengue during World War II. , 1952, The American journal of tropical medicine and hygiene.

[6]  M. Sinniah,et al.  Dengue haemorrhagic fever and dengue shock syndrome: are they tumour necrosis factor-mediated disorders? , 1991, FEMS microbiology immunology.

[7]  M. Kazatchkine,et al.  Pathogenesis of dengue: an alternative hypothesis. , 1990, The Southeast Asian journal of tropical medicine and public health.

[8]  A. Nisalak,et al.  Human immune responses to dengue viruses. , 1990, The Southeast Asian journal of tropical medicine and public health.

[9]  S. Nimmannitya,et al.  Clinical spectrum and management of dengue haemorrhagic fever. , 1987, The Southeast Asian journal of tropical medicine and public health.

[10]  I. Kurane,et al.  Immunity and immunopathology in dengue virus infections. , 1992, Seminars in immunology.

[11]  M. Sharma,et al.  Increased capillary permeability mediated by a dengue virus-induced lymphokine. , 1990, Immunology.

[12]  S. Halstead,et al.  Antibody, macrophages, dengue virus infection, shock, and hemorrhage: a pathogenetic cascade. , 1989, Reviews of infectious diseases.

[13]  F. Ennis,et al.  Dengue virus-specific human T cell clones. Serotype crossreactive proliferation, interferon gamma production, and cytotoxic activity , 1989, The Journal of experimental medicine.

[14]  R. Tan,et al.  Some clinical and epidemiological observations on virologically confirmed dengue hemorrhagic fever. , 1990, Paediatrica Indonesiana.

[15]  Y. A. Kasim,et al.  Hyperventilation in children with dengue hemorrhagic fever (DHF). , 2019, Paediatrica Indonesiana.

[16]  S. Halstead The Alexander D. Langmuir Lecture. The pathogenesis of dengue. Molecular epidemiology in infectious disease. , 1981, American journal of epidemiology.

[17]  S. Lam,et al.  Dengue haemorrhagic fever , 1995 .

[18]  M. Guzmán,et al.  Dengue haemorrhagic fever/dengue shock syndrome: lessons from the Cuban epidemic, 1981. , 1989, Bulletin of the World Health Organization.

[19]  S. Jota,et al.  Pericardial effusion in dengue haemorrhagic fever. , 2018, Paediatrica Indonesiana.

[20]  R. Dhawan,et al.  Effect of dengue virus-induced cytotoxin on capillary permeability. , 1990, Journal of experimental pathology.

[21]  R. Dhawan,et al.  Dengue virus‐induced human cytotoxic factor: production by peripheral blood leucocytes in vitro , 1995, Clinical and experimental immunology.

[22]  S. Halstead,et al.  Pathogenesis of dengue: challenges to molecular biology. , 1988, Science.

[23]  A. Nisalak,et al.  Activation of T lymphocytes in dengue virus infections. High levels of soluble interleukin 2 receptor, soluble CD4, soluble CD8, interleukin 2, and interferon-gamma in sera of children with dengue. , 1991, The Journal of clinical investigation.

[24]  D. Hober,et al.  Serum Levels of Tumor Necrosis Factor-α (TNF-α), Interleukin-6 (IL-6), and Interleukin-1β (IL-1β) in Dengue-Infected Patients , 1993 .

[25]  M. Mirić,et al.  Interferon and thymic hormones in the therapy of human myocarditis and idiopathic dilated cardiomyopathy. , 1995, European heart journal.

[26]  Kim PATHOGENESIS OF DENGUE. , 1988 .

[27]  H. Schultheiss,et al.  Immunohistochemistry in dilated cardiomyopathy. , 1995, European heart journal.